Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson's Disease Dementia (PDD)
Principal Investigator (?)
A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia associated with LBD (PDD or DLB).
Eli Lilly, Co.
Available at the following location(s)